Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Within the registrational trial, investigators will compare a single dose of 4D-150 to treatment with standard anti-VEGF therapy.

Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel ...

D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

This was the stock's fourth consecutive day of losses.

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...